Benjamin A. Toll PhD
Lecturer in Psychiatry; Program Director, Smoking Cessation Service at Smilow Cancer Hospital at Yale-New Haven
Smoking cessation clinical trials; Quitline studies; Smoking cessation with cancer patients; Secondary analyses of clinical trial data; Analyses of mediators and moderators of treatment; Assessment, methods, and psychometrics
- “Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers” This project will be a secondary analysis of our New York State Smokers’ Quitline data.
- “Smoking Cessation to Improve Survival Rates of Head and Neck Cancer Patients” This project is an 8-week, open label clinical trial comparing smoking cessation treatment with varenicline 2 mg to nicotine patch 21 mg in a sample of 30 patients who completed treatment for head and neck cancer.
Dr. Toll conducts smoking cessation studies aimed at developing novel treatments (both counseling and drug treatments). He is currently testing treatments that emphasize the positive aspects of quitting smoking (e.g., quitting will add years to your life) and interventions aimed at reducing alcohol use amongst smokers who drink at hazardous levels. He is also conducting research aimed at improving the quality of measures of cigarette consumption (e.g., IVR) and smoking related syndromes (e.g., withdrawal).
Extensive Research Description
Dr. Toll’s primary research interest involves developing novel psychosocial and pharmacological treatments for tobacco use disorders. Current studies focus on message framing to promote smoking cessation. He has been working with the New York State Smokers' Quitline on studies testing gain-framed counseling (e.g., if you quit smoking you will live longer) and mediators and moderators of responses to gain-framed counseling. He has also been working on studies of naltrexone for minimization of post smoking cessation weight gain. In addition, Dr. Toll is involved in several studies of psychometrics, assessment, and methodological issues with addictive behaviors.